» Articles » PMID: 37303668

Multifaceted Roles of Fcγ Receptors in COVID-19 and Vaccine Responses

Overview
Journal Am J Transl Res
Specialty General Medicine
Date 2023 Jun 12
PMID 37303668
Authors
Affiliations
Soon will be listed here.
Abstract

Recent data have revealed various effector functions of FcγRs in immune responses against challenges with SARS-CoV-2 virus. FcγRs act as a bridge between antibody specificity and effector cells. In many cases, IgG/FcγR interactions generate cell-mediated immune protection from infection via ADCP or ADCC. These responses are beneficial, as they may participate in virus elimination and persist longer than neutralizing anti-Spike antibodies. In contrast, these interactions may sometimes prove beneficial to the virus by enhancing viral uptake into phagocytic cells via ADE and causing excessive inflammation. Here, we summarize key features of FcγRs, discuss effector functions, clinical relevance, and factors influencing FcγR-mediated immune responses in COVID-19 and vaccine responses, and consider IVIg and kinase inhibitors for targeting FcγRs signaling in COVID-19.

Citing Articles

ULV: A robust statistical method for clustered data, with applications to multi-subject, single-cell omics data.

Du M, Johnston K, Berrocal V, Li W, Xu X, Yu Z ArXiv. 2024; .

PMID: 38947924 PMC: 11213121.

References
1.
Nimmerjahn F, Ravetch J . Fc-receptors as regulators of immunity. Adv Immunol. 2007; 96:179-204. DOI: 10.1016/S0065-2776(07)96005-8. View

2.
Vidarsson G, Dekkers G, Rispens T . IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014; 5:520. PMC: 4202688. DOI: 10.3389/fimmu.2014.00520. View

3.
Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer A, Ginn H . Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021; 184(9):2348-2361.e6. PMC: 7901269. DOI: 10.1016/j.cell.2021.02.037. View

4.
Ricke D . Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Front Immunol. 2021; 12:640093. PMC: 7943455. DOI: 10.3389/fimmu.2021.640093. View

5.
Bournazos S, Klein F, Pietzsch J, Seaman M, Nussenzweig M, Ravetch J . Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014; 158(6):1243-1253. PMC: 4167398. DOI: 10.1016/j.cell.2014.08.023. View